| Literature DB >> 31350436 |
Laura Lozza1, Pedro Moura-Alves2,3, Teresa Domaszewska4, Carolina Lage Crespo5, Ioana Streata6, Annika Kreuchwig7, Andreas Puyskens4, Marina Bechtle4, Marion Klemm4, Ulrike Zedler4, Bogdan Silviu Ungureanu8, Ute Guhlich-Bornhof4, Anne-Britta Koehler4, Manuela Stäber4, Hans-Joachim Mollenkopf9, Robert Hurwitz10, Jens Furkert7, Gerd Krause7, January Weiner4, António Jacinto5, Ioana Mihai6, Maria Leite-de-Moraes11, Frank Siebenhaar12, Marcus Maurer12, Stefan H E Kaufmann13,14.
Abstract
As a first host barrier, the skin is constantly exposed to environmental insults that perturb its integrity. Tight regulation of skin homeostasis is largely controlled by the aryl hydrocarbon receptor (AhR). Here, we demonstrate that Henna and its major pigment, the naphthoquinone Lawsone activate AhR, both in vitro and in vivo. In human keratinocytes and epidermis equivalents, Lawsone exposure enhances the production of late epidermal proteins, impacts keratinocyte differentiation and proliferation, and regulates skin inflammation. To determine the potential use of Lawsone for therapeutic application, we harnessed human, murine and zebrafish models. In skin regeneration models, Lawsone interferes with physiological tissue regeneration and inhibits wound healing. Conversely, in a human acute dermatitis model, topical application of a Lawsone-containing cream ameliorates skin irritation. Altogether, our study reveals how a widely used natural plant pigment is sensed by the host receptor AhR, and how the physiopathological context determines beneficial and detrimental outcomes.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31350436 PMCID: PMC6659674 DOI: 10.1038/s41598-019-47350-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Henna and Lawsone activate AhR in HaCaT and human primary keratinocytes. (A) Chemical structures of TCDD, Phthiocol (Pht) and Lawsone (Law) and (B) in silico modeling studies predicting binding of these molecules in the AhR binding pocket. Upper panel: 2D-interaction plot (LigandScout 4.1), hydrogen-donor (green dashed), -acceptor (red dashed), hydrophobic (orange); lower panel: 3D-interaction models, hydrogen bonds (yellow dashed), potential halogen bond (green dashed). (C) Luciferase activity of AhR reporter HaCaT cells stimulated for 4 hours (h) with TCDD, Phthiocol (Pht), Henna or Lawsone (Law). (D) Dose dependent CYP1A1 expression of HEK cells stimulated for 4 h, in the presence (black dots) or absence (red dots) of the AhR inhibitor CH223191 (CH, 12 µM) normalized to control DMSO in the absence of Lawsone. (E) CYP1A1 and AHRR expression after 4 h Lawsone (10 µM) stimulation of HEK cells normalized to DMSO. Each dot represents one individual. (F-G) HEK cells were transiently transfected with AhR-siRNA (siAhR) or Scramble control (siScr) in different individuals (dots). Each color depicts results of the same individual. (F) AhR knockdown validation relative to non-transfected wild type (WT) cells. (G) CYP1A1 expression after 4 h stimulation with Lawsone normalized to DMSO. (H) 48 h CYP1A1 enzymatic activity in HEK cells treated with Lawsone (10 µM) normalized to DMSO. (I) AhR-target gene enrichment after Lawsone stimulation (10 µM) relative to TLR2 stimulation (Pam2CSK4, 300 ng/mL). Area under the curve (AUC), q-values and highly enriched genes are indicated. (C,E–H) Data from at least 3 independent experiments are shown. (D) Data from 1 representative experiment out of 2 is shown. (C) Mean + S.E.M., (D) Mean, (E–H) Floating bars, Mean Min to Max. and. (E,H) Student’s t-test, (F,G) One-way ANOVA with Fisher’s test. *P < 0.05; **P < 0.01; ***P < 0.001.
AhR dependent genes.
| Name | Gene | References |
|---|---|---|
| Cytochrome P450, family 1, member A1 | CYP1A1 | Hankinson, 1995; Katiyar |
| Cytochrome P450, family 1, member B1 | CYP1B1 | Hankinson, 1995; Katiyar |
| Aryl hydrocarbon receptor repressor | AHRR | Baba |
| TCDD-inducible poly(ADP-ribose) polymerase | TIPARP | Lo and Matthews, 2012; Frericks |
| Interleukin-1β | IL-1β | Sutter |
| plasminogen activator inhibitor-2 | PAI-2 | Sutter |
| epiregulin | EREG | Patel |
| amphiregulin | AREG | Du |
| insulin-like growth factor 1 receptor | IGFR1 | Lo and Matthews, 2012 |
| NADP(H):quinone oxidoreductase 1 | NQO1 | Wang |
The table includes AhR target genes containing the xenobiotic-responsive element (XRE) in the promoter region and genes described to be induced by AhR activation.
Nrf2-related genes.
| Name | Gene | Reference |
|---|---|---|
| glutamate-cysteine ligase, catalytic subunit | GCLC | Baird L., Arch Toxicol (2011) 85:241–272 |
| NAD(P)H dehydrogenase, quinone 1 | NQO1 | |
| ferritin, light polypeptide | FTL | |
| glutathione S-transferase alpha 1 | GSTA1 | |
| glutathione S-transferase alpha 2 | GSTA2 | |
| glutathione S-transferase alpha 3 | GSTA3 | |
| glutathione S-transferase alpha 4 | GSTA4 | |
| glutathione S-transferase alpha 5 | GSTA5 | |
| glutathione S-transferase alpha 6, pseudogene | GSTA6P | |
| glutathione S-transferase alpha 7, pseudogene | GSTA7P | |
| glutathione S-transferase mu 1 | GSTM1 | |
| glutathione S-transferase mu 2 (muscle) | GSTM2 | |
| glutathione S-transferase mu 3 (brain) | GSTM3 | |
| glutathione S-transferase mu 4 | GSTM4 | |
| glutathione S-transferase mu 5 | GSTM5 | |
| glutathione S-transferase omega 1 | GSTO1 | |
| glutathione S-transferase omega 2 | GSTO2 | |
| glutathione S-transferase omega 3, pseudogene | GSTO3P | |
| glutathione S-transferase pi 1 | GSTP1 | |
| glutathione S-transferase theta 1 | GSTT1 | |
| glutathione S-transferase theta 2 (gene/pseudogene) | GSTT2 | |
| glutathione S-transferase theta 2B (gene/pseudogene) | GSTT2B | |
| glutathione S-transferase zeta 1 | GSTZ1 | |
| hematopoietic prostaglandin D synthase | HPGDS | |
| aldo-keto reductase family 1, member A1 (aldehyde reductase) | AKR1A1 | |
| aldo-keto reductase family 1, member B1 (aldose reductase) | AKR1B1 | |
| aldo-keto reductase family 1, member B10 (aldose reductase) | AKR1B10 | |
| aldo-keto reductase family 1, member B15 | AKR1B15 | |
| aldo-keto reductase family 1, member C1 | AKR1C1 | |
| aldo-keto reductase family 1, member C2 | AKR1C2 | |
| aldo-keto reductase family 1, member C3 | AKR1C3 | |
| aldo-keto reductase family 1, member C4 | AKR1C4 | |
| aldo-keto reductase family 1, member D1 | AKR1D1 | |
| aldo-keto reductase family 1, member E2 | AKR1E2 | |
| aldo-keto reductase family 7, member A2 | AKR7A2 | |
| aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase) | AKR7A3 | |
| potassium channel, voltage gated subfamily A regulatory beta subunit 1 | KCNAB1 | |
| potassium channel, voltage gated subfamily A regulatory beta subunit 2 | KCNAB2 | |
| potassium channel, voltage gated subfamily A regulatory beta subunit 3 | KCNAB3 | |
| ATP-binding cassette, sub-family C (CFTR/MRP), member 1 | ABCC1 | |
| ATP-binding cassette, sub-family C (CFTR/MRP), member 2 | ABCC2 | |
| ATP-binding cassette, sub-family C (CFTR/MRP), member 3 | ABCC3 | |
| ATP-binding cassette, sub-family C (CFTR/MRP), member 4 | ABCC4 | |
| ATP-binding cassette, sub-family C (CFTR/MRP), member 5 | ABCC5 | |
| ATP-binding cassette, sub-family C (CFTR/MRP), member 6 | ABCC6 | |
| ATP-binding cassette, sub-family C (CFTR/MRP), member 8 | ABCC8 | |
| ATP-binding cassette, sub-family C (CFTR/MRP), member 9 | ABCC9 | |
| ATP-binding cassette, sub-family C (CFTR/MRP), member 10 | ABCC10 | |
| ATP-binding cassette, sub-family C (CFTR/MRP), member 11 | ABCC11 | |
| ATP-binding cassette, sub-family C (CFTR/MRP), member 12 | ABCC12 | |
| ATP-binding cassette, sub-family C (CFTR/MRP), member 13, pseudogene | ABCC13 | |
| cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) | CFTR | |
| UDP glucuronosyltransferase 1 family, polypeptide A complex locus | UGT1A | |
| UDP glucuronosyltransferase 1 family, polypeptide A1 | UGT1A1 | |
| UDP glucuronosyltransferase 1 family, polypeptide A2 pseudogene | UGT1A2P | |
| UDP glucuronosyltransferase 1 family, polypeptide A3 | UGT1A3 | |
| UDP glucuronosyltransferase 1 family, polypeptide A4 | UGT1A4 | |
| UDP glucuronosyltransferase 1 family, polypeptide A5 | UGT1A5 | |
| UDP glucuronosyltransferase 1 family, polypeptide A6 | UGT1A6 | |
| UDP glucuronosyltransferase 1 family, polypeptide A7 | UGT1A7 | |
| UDP glucuronosyltransferase 1 family, polypeptide A8 | UGT1A8 | |
| UDP glucuronosyltransferase 1 family, polypeptide A9 | UGT1A9 | |
| UDP glucuronosyltransferase 1 family, polypeptide A10 | UGT1A10 | |
| UDP glucuronosyltransferase 1 family, polypeptide A11 pseudogene | UGT1A11P | |
| UDP glucuronosyltransferase 1 family, polypeptide A12 pseudogene | UGT1A12P | |
| UDP glucuronosyltransferase 1 family, polypeptide A13 pseudogene | UGT1A13P | |
| UDP glucuronosyltransferase 2 family, polypeptide A1, complex locus | UGT2A1 | |
| UDP glucuronosyltransferase 2 family, polypeptide A2 | UGT2A2 | |
| UDP glucuronosyltransferase 2 family, polypeptide A3 | UGT2A3 | |
| UDP glucuronosyltransferase 2 family, polypeptide B4 | UGT2B4 | |
| UDP glucuronosyltransferase 2 family, polypeptide B7 | UGT2B7 | |
| UDP glucuronosyltransferase 2 family, polypeptide B10 | UGT2B10 | |
| UDP glucuronosyltransferase 2 family, polypeptide B11 | UGT2B11 | |
| UDP glucuronosyltransferase 2 family, polypeptide B15 | UGT2B15 | |
| UDP glucuronosyltransferase 2 family, polypeptide B17 | UGT2B17 | |
| UDP glucuronosyltransferase 2 family, polypeptide B24 pseudogene | UGT2B24P | |
| UDP glucuronosyltransferase 2 family, polypeptide B25 pseudogene | UGT2B25P | |
| UDP glucuronosyltransferase 2 family, polypeptide B26 pseudogene | UGT2B26P | |
| UDP glucuronosyltransferase 2 family, polypeptide B27 pseudogene | UGT2B27P | |
| UDP glucuronosyltransferase 2 family, polypeptide B28 | UGT2B28 | |
| UDP glucuronosyltransferase 2 family, polypeptide B29 pseudogene | UGT2B29P | |
| UDP glycosyltransferase 3 family, polypeptide A1 | UGT3A1 | |
| UDP glycosyltransferase 3 family, polypeptide A2 | UGT3A2 | |
| UDP glycosyltransferase 8 | UGT8 |
The table includes Nrf2 target genes.
Figure 2Lawsone stimulation modulates keratinocyte proliferation and differentiation. (A) Nuc red Live 647 positive HEK cells at different time points after stimulation with Lawsone (Law, 10 µM) and Phthiocol (Pht, 50 µM), compared to DMSO. (B) Epidermal differentiation complex and keratin gene enrichment of HEK cells after Lawsone stimulation (10 μM) and relative to TLR2 stimulation (Pam2CSK4, 0.236 μM) at (left) 4 h and (right) 24 h. Area under the curve (AUC), q-value and highly enriched genes are indicated. (C) KRT2, CNFN, HRNR, LCE3D and FLG2 expression of HEK cells after 24 h stimulation with Lawsone (10 µM) normalized to DMSO. Each color depicts results of the same individual. (D) LCE3D, KRT2, HRNR and CNFN expression on HEK cells transfected with AhR-siRNA (siAhR) or Scramble control (siScr) and further stimulated for 24 h with Lawsone (10 μM). Values are relative to siScr. Each color depicts results of the same individual. (E, top) Epidermal skin equivalents were stimulated for 5d with Lawsone (10 µM) or DMSO and stained with DAPI (blue) and the proliferation marker KI67 (purple). (E, bottom) Percentage of KI67 positive cells normalized to the total number of cells (DAPI). (F) Representative of an in vitro epidermis model experiment stained for Cornifelin (red) and Loricrin (green) and (G) protein expression of Filaggrin, Cornifelin and Loricrin at day 5 or 10 of culture after stimulation with 10 or 100 µM of Lawsone (blots were cropped from the same gel. Full unedited gels are provided in Supplementary Data). (A,C) Data from 3 independent experiments are shown. (D) Data from 2 independent donors. (E top, F,G) One representative experiment out of 2 is shown. (E) Pooled data from 2 different experiments is shown. (A) Mean + S.E.M., (C–E bottom) Floating bars, Mean Min to Max. (A) Two-way ANOVA with Fisher’s test, (C) One-way ANOVA with Dunn’s test. (E, bottom) Student’s t-test. *P < 0.05; **P < 0.01, ***P < 0.001, ****P < 0.0001.
Epidermal differentiation complex and keratin genes.
| approved symbol | approved name | categories | References | |
|---|---|---|---|---|
| Keratin type I | KRT9 | keratin 9, type I | Human type I epithelial keratins | Schweizer |
| KRT10 | keratin 10, type I | Human type I epithelial keratins | ||
| KRT12 | keratin 12, type I | Human type I epithelial keratins | ||
| KRT13 | keratin 13, type I | Human type I epithelial keratins | ||
| KRT14 | keratin 14, type I | Human type I epithelial keratins | ||
| KRT15 | keratin 15, type I | Human type I epithelial keratins | ||
| KRT16 | keratin 16, type I | Human type I epithelial keratins | ||
| KRT17 | keratin 17, type I | Human type I epithelial keratins | ||
| KRT18 | keratin 18, type I | Human type I epithelial keratins | ||
| KRT19 | keratin 19, type I | Human type I epithelial keratins | ||
| KRT20 | keratin 20, type I | Human type I epithelial keratins | ||
| KRT23 | keratin 23, type I | Human type I epithelial keratins | ||
| KRT24 | keratin 24, type I | Human type I epithelial keratins | ||
| KRT25 | keratin 25, type I | Human type I epithelial keratins | ||
| KRT26 | keratin 26, type I | Human type I epithelial keratins | ||
| KRT27 | keratin 27, type I | Human type I epithelial keratins | ||
| KRT28 | keratin 28, type I | Human type I epithelial keratins | ||
| keratin type II | KRT1 | keratin 1, type II | Human type II epithelial keratins | Schweizer |
| KRT2 | keratin 2, type II | Human type II epithelial keratins | ||
| KRT3 | keratin 3, type II | Human type II epithelial keratins | ||
| KRT4 | keratin 4, type II | Human type II epithelial keratins | ||
| KRT5 | keratin 5, type II | Human type II epithelial keratins | ||
| KRT6A | keratin 6A, type II | Human type II epithelial keratins | ||
| KRT6B | keratin 6B, type II | Human type II epithelial keratins | ||
| KRT6C | keratin 6C, type II | Human type II epithelial keratins | ||
| KRT7 | keratin 7, type II | Human type II epithelial keratins | ||
| KRT8 | keratin 8, type II | Human type II epithelial keratins | ||
| KRT71 | keratin 71, type II | Human type II epithelial keratins | ||
| KRT72 | keratin 72, type II | Human type II epithelial keratins | ||
| KRT73 | keratin 73, type II | Human type II epithelial keratins | ||
| KRT74 | keratin 74, type II | Human type II epithelial keratins | ||
| KRT75 | keratin 75, type II | Human type II epithelial keratins | ||
| KRT76 | keratin 76, type II | Human type II epithelial keratins | ||
| KRT77 | keratin 77, type II | Human type II epithelial keratins | ||
| KRT78 | keratin 78, type II | Human type II epithelial keratins | ||
| KRT79 | keratin 79, type II | Human type II epithelial keratins | ||
| KRT80 | keratin 80, type II | Human type II epithelial keratins | ||
| non epidermal differentiation complex-associated | CNFN | Cornifelin | Kennedy | |
| epidermal differentiation complex | CRNN | Cornulin | Mischke | |
| FLG | Filaggrin | |||
| FLG2 | Filaggrin Family Member 2 | |||
| HRNR | Hornerin | |||
| IVL | Involucrin | |||
| LCE1A | Late Cornified Envelope 1A | |||
| LCE1B | Late Cornified Envelope 1B | |||
| LCE1C | Late Cornified Envelope 1C | |||
| LCE1D | Late Cornified Envelope 1D | |||
| LCE1E | Late Cornified Envelope 1E | |||
| LCE1F | Late Cornified Envelope 1F | |||
| LCE2A | Late Cornified Envelope 2A | |||
| LCE2B | Late Cornified Envelope 2B | |||
| LCE2C | Late Cornified Envelope 2C | |||
| LCE2D | Late Cornified Envelope 2D | |||
| LCE3A | Late Cornified Envelope 3A | |||
| LCE3B | Late Cornified Envelope 3B | |||
| LCE3C | Late Cornified Envelope 3C | |||
| LCE3D | Late Cornified Envelope 3D | |||
| LCE3E | Late Cornified Envelope 3E | |||
| LCE4A | Late Cornified Envelope 4A | |||
| LCE5A | Late Cornified Envelope 5A | |||
| LCE6A | Late Cornified Envelope 6A | |||
| LEP7 | Late Envelope Protein 7 | |||
| LOR | Loricrin | |||
| NICE-1 | Cysteine-Rich C-Terminal 1 | |||
| RPTN | Repetin | |||
| S100A1 | S100 Calcium Binding Protein A1 | |||
| S100A2 | S100 Calcium Binding Protein A2 | |||
| S100A3 | S100 Calcium Binding Protein A3 | |||
| S100A4 | S100 Calcium Binding Protein A4 | |||
| S100A5 | S100 Calcium Binding Protein A5 | |||
| S100A6 | S100 Calcium Binding Protein A6 | |||
| S100A7 | S100 Calcium Binding Protein A7 | |||
| S100A8 | S100 Calcium Binding Protein A8 | |||
| S100A9 | S100 Calcium Binding Protein A9 | |||
| S100A10 | S100 Calcium Binding Protein A10 | |||
| S100A11 | S100 Calcium Binding Protein A11 | |||
| S100A12 | S100 Calcium Binding Protein A12 | |||
| S100A13 | S100 Calcium Binding Protein A13 | |||
| S100A14 | S100 Calcium Binding Protein A14 | |||
| S100A15 | S100 Calcium Binding Protein A15 | |||
| S100A16 | S100 Calcium Binding Protein A16 | |||
| S100A7L2 | S100 Calcium Binding Protein A7-Like 2 | |||
| SPRR1A | small proline-rich proteins 1A | |||
| SPRR1B | small proline-rich proteins 1B | |||
| SPRR2A | small proline-rich proteins 2A | |||
| SPRR2B | small proline-rich proteins 2B | |||
| SPRR2C | small proline-rich proteins 2C | |||
| SPRR2D | small proline-rich proteins 2D | |||
| SPRR2E | small proline-rich proteins 2E | |||
| SPRR2F | small proline-rich proteins 2F | |||
| SPRR2G | small proline-rich proteins 2G | |||
| SPRR3 | small proline-rich proteins 3 | |||
| SPRR4 | small proline-rich proteins 4 | |||
| THH | Trichohyalin | |||
| THHL1 | Trichohyalin-Like 1 |
The table includes genes of the epidermal differentiation complex and keratins.
Figure 3Henna and Lawsone activate AhR in zebrafish larvae. (A,B) Fold induction of CYP1A, AhRRa and AhRRb transcripts from zebrafish larvae (2 days post-fertilization, dpf) treated (red squares) or not (black circles) for 2 h with 5 µM of AhR inhibitor CH223191, followed by further 4 h stimulation with (A) Henna (equivalent to 10 μM Lawsone), (B) Lawsone (10 μM) or DMSO vehicle control. Triplicates of 12 larvae depicted in each data point. (C) Scheme of the semi-high throughput experimental design developed to measure zebrafish larvae CYP1A enzymatic activity. (D) Representative images obtained upon CYP1A activity measurements using an Array Scan TM XTI Live High Content Platform. (E) CYP1A enzymatic activity expressed as total intensity of resorufin detected per larva (each dot represents one larva). 1 representative experiment out of 3 are shown (n = 36 larvae per condition). (A,B) Data from 1 representative experiment out of 3 is shown. (A,B) Floating bars, Mean Min to Max. (A,B) Two-way ANOVA with Bonferroni’s test. (E) Two-way ANOVA with Fisher’s test. **P < 0.01, ***P < 0.001; ****P < 0.0001.
Figure 4Lawsone inhibits wound healing and skin regeneration in vivo. (A) Representative images of zebrafish fin regeneration 3 days post amputation (dpa) and exposure to different stimuli. Regenerated area depicted in red. (B) Quantification of the zebrafish tail fin area regenerated, normalized to DMSO treated larvae. (C) Neutrophil migration to zebrafish tailfin wounds visualized in DMSO or Lawsone-treated transgenic larvae Tg(mpeg.mCherryCAAX SH378 mpx:GFP i114). Frames from representative movies of migrating leukocytes in the wounded tail fin are shown. The lines indicate tracking of individual neutrophils over the indicated time point of the experiment. Wound is represented with a white dashed line. (D) 2D tracks of individual neutrophils migrating in the tail fin of wounded neutrophil-GFP zebrafish 3dpf larvae exposed to 10 µM Lawsone (n = 8) or DMSO (n = 23). (E) Quantification of 2D directionality, Forward migration index (FMI), accumulated distance and speed of individual leukocytes in the wounded tailfin. (B) Pooled data from 4 independent experiments with at least 24 larvae per condition per experiment, Mean + S.E.M., (E) Data from 2 pooled experiments, Mean + S.E.M. (B) One-way ANOVA with Fisher’s test, (E) Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001; n.s.-not significant.
Psoriasis and dermatitis differentialy regulated genes.
| Symbol | logFc. (Law vs DMSO at 24 h) | p-value |
|---|---|---|
| IFIT1 | −2,58 | 5,53E-21 |
| MX1 | −2,31 | 9,39E-17 |
| ISG15 | −2,20 | 3,06E-17 |
| ISG15 | −2,19 | 3,06E-17 |
| IFIT3 | −1,69 | 3,19E-13 |
| IFI6 | −1,66 | 7,69E-17 |
| IFI44 | −1,54 | 1,29E-12 |
| EPSTI1 | −1,44 | 1,36E-11 |
| IFNK | −1,24 | 4,32E-10 |
| TOP2A | −1,22 | 2,13E-10 |
| IFIH1 | −1,20 | 3,84E-11 |
| PPP1R3C | −1,20 | 1,44E-10 |
| SAMD9L | −1,12 | 3,91E-07 |
| IGFBP3 | −1,10 | 3,71E-13 |
| PARP9 | −1,10 | 6,15E-09 |
| PARP9 | −1,10 | 6,15E-09 |
| MKI67 | −1,08 | 5,65E-10 |
| OAS2 | −1,07 | 1,70E-05 |
| SOCS1 | −1,02 | 3,30E-10 |
| EFNB2 | −1,01 | 1,65E-07 |
| OAS1 | −0,99 | 3,67E-07 |
| CTSL2 | −0,98 | 1,34E-07 |
| DDX58 | −0,97 | 9,52E-05 |
| IRF9 | −0,97 | 2,64E-07 |
| PDK4 | −0,95 | 0,000375155 |
| SYNE2 | −0,95 | 6,10E-06 |
| CSPG4 | −0,92 | 3,75E-09 |
| SGK1 | −0,92 | 2,15E-09 |
| IFI44L | −0,90 | 3,19E-05 |
| EIF2AK2 | −0,89 | 2,34E-05 |
| RTP4 | −0,88 | 2,53E-06 |
| KRT15 | −0,87 | 9,02E-05 |
| SPC25 | −0,87 | 9,74E-08 |
| ANXA1 | −0,85 | 1,61E-08 |
| LAMP3 | −0,85 | 2,63E-09 |
| CAV1 | −0,84 | 0,00298468 |
| CCL27 | −0,82 | 1,16E-06 |
| DSG1 | −0,81 | 4,72E-08 |
| SP100 | −0,81 | 4,12E-06 |
| STAT1 | −0,79 | 2,37E-09 |
| TAGLN | −0,78 | 1,02E-05 |
| GJB2 | −0,78 | 2,33E-05 |
| PBK | −0,78 | 4,38E-07 |
| CCNA2 | −0,77 | 3,25E-08 |
| TIMP3 | −0,77 | 4,81E-07 |
| ANXA2 | −0,75 | 0,000797819 |
| GBP2 | −0,73 | 3,67E-06 |
| IL15 | −0,72 | 2,30E-05 |
| AHNAK | −0,71 | 0,005674451 |
| JUN | −0,70 | 9,43E-08 |
| ID4 | −0,70 | 0,000169748 |
| IL33 | −0,68 | 0,000121647 |
| TLR3 | −0,68 | 2,94E-05 |
| OPTN | −0,67 | 8,05E-07 |
| SLC6A2 | −0,67 | 8,47E-06 |
| JAK2 | −0,66 | 0,009480402 |
| NR3C1 | −0,65 | 9,22E-05 |
| PTRF | −0,64 | 1,47E-07 |
| BLNK | −0,64 | 0,000567571 |
| CAMK2N1 | −0,63 | 5,82E-06 |
| P4HA2 | −0,63 | 0,019848721 |
| FGF7 | −0,63 | 0,00122151 |
| IFIT5 | −0,60 | 4,69E-06 |
| MX2 | −0,58 | 0,003413461 |
| USP18 | −0,53 | 4,04E-05 |
| TRIM21 | −0,53 | 0,012172344 |
| OAS3 | −0,52 | 0,002218834 |
| ITSN2 | −0,47 | 0,010777607 |
| IFI35 | −0,39 | 0,039516673 |
| BATF2 | −0,39 | 0,041688705 |
| PNPT1 | −0,29 | 0,037644415 |
| PML | −0,22 | 0,030117951 |
| MAP3K9 | 0,34 | 0,010663036 |
| FIGF | 0,60 | 0,000923682 |
| DUSP2 | 0,65 | 0,000736741 |
| S100A8 | 0,65 | 7,22E-08 |
| ALOX12B | 0,66 | 6,43E-06 |
| EGR1 | 0,66 | 3,18E-06 |
| MANF | 0,66 | 1,07E-07 |
| CST6 | 0,67 | 5,62E-06 |
| CPNE7 | 0,67 | 2,13E-06 |
| POMC | 0,68 | 0,000202198 |
| FSCN1 | 0,69 | 4,83E-07 |
| PPIF | 0,70 | 7,83E-07 |
| PGD | 0,71 | 2,20E-05 |
| CSK | 0,73 | 0,016210156 |
| MPHOSPH6 | 0,74 | 1,41E-06 |
| FABP5 | 0,77 | 1,47E-09 |
| CBR1 | 0,82 | 1,16E-05 |
| CHRM1 | 0,85 | 4,90E-06 |
| TNXB | 0,86 | 5,07E-06 |
| S100A9 | 0,86 | 1,09E-09 |
| WNT5A | 0,86 | 1,11E-08 |
| LCN2 | 0,88 | 1,41E-06 |
| AhRR | 0,90 | 2,04E-05 |
| AREG | 0,93 | 4,67E-07 |
| IFI30 | 1,00 | 4,21E-11 |
| HMOX1 | 1,05 | 1,50E-11 |
| MMP1 | 1,05 | 4,94E-12 |
| GAL | 1,12 | 3,20E-11 |
| IL1A | 1,20 | 4,85E-12 |
| SPRR1A | 1,20 | 2,65E-13 |
| IL36G | 1,23 | 7,89E-11 |
| EPHX1 | 1,24 | 0,000139207 |
| ARG1 | 1,29 | 2,74E-13 |
| SERPINB3 | 1,33 | 1,13E-10 |
| EREG | 1,35 | 5,67E-11 |
| SERPINB4 | 1,46 | 3,19E-08 |
| ALDH1A3 | 1,48 | 8,05E-11 |
| TGM3 | 1,49 | 1,42E-07 |
| SLC45A4 | 1,59 | 1,85E-11 |
| SECTM1 | 1,70 | 1,96E-13 |
| SPRR2C | 1,98 | 1,08E-14 |
| IL1B | 2,50 | 1,11E-19 |
| CYP1A1 | 4,70 | 4,98E-23 |
| CYP1B1 | 5,56 | 1,51E-22 |
The table includes the genes involved in psoriasis and dermatitis that are differentialy regulated upon stimulation with Lawsone.
Figure 5Lawsone ameliorates skin recovery in a model of human contact skin irritation. (A) Representative images of blood flux measured using the MoorFLPI-2 Full_Field Laser Perfusion Imager V1.1 software at 48-72-96 h and 7 days upon application of 0.5% SDS. Cream containing increasing concentration of Lawsone (% of Lawsone = weight of Lawsone (g) per 100 g of cream) was applied 24 h after SDS treatment. (B) Example of (top) irritation spots and (bottom) blood flux quantification. After SDS applicationall individuals were treated as follow: far left: control cream, left: 0.5%; right 1%; far right 3% Lawsone cream. (C) Percentage of flux reduction at different time points normalized to the respective average flux intensity measured at 48 h post-SDS application. (A) Representative responses of 2 out of 9 volunteers are shown. (C) Data from 9 individuals are shown. One-way ANOVA with Fisher’s test. *P < 0.05; **P < 0.01; ***P < 0.001.